ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
Rhea-AI Summary
ADMA (Nasdaq: ADMA) announced a 2026 capital return initiative targeting $200 million, including a $125 million accelerated share repurchase (ASR) with JPMorgan, and plans to complete the ASR within about five months.
The company will initially receive ~6.4 million shares (≈80% of expected ASR shares) based on a $15.57 close on Feb 27, 2026, and retains up to $500 million authorized repurchases.
Positive
- $125M ASR executed with JPMorgan
- Capital return target of $200M for 2026
- Initially received ~6.4M shares (~80% of ASR)
- Up to $500M total repurchase authorization
Negative
- Final ASR share count depends on VWAP and an agreed discount
- At settlement, company may need to deliver shares or pay cash
- Repurchases could limit near-term cash available for other investments
News Market Reaction – ADMA
On the day this news was published, ADMA gained 6.49%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $249M to the company's valuation, bringing the market cap to $4.08B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ADMA was up 2.57% while key biotech peers showed mixed moves: ZLAB +1.42%, ACAD +0.90%, MIRM +1.41%, PTGX +4.42%, and MTSR -0.34%. No peers appeared in the momentum scanner and there were no same-day peer headlines, suggesting this buyback news was more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Earnings results | Positive | +1.0% | Record FY2025 results with strong revenue, ASCENIV growth, and higher long-term guidance. |
| Feb 18 | Earnings date set | Neutral | +0.3% | Announcement of Q4 and FY2025 earnings release date and accompanying conference call. |
| Jan 12 | Preliminary results | Positive | -0.1% | Preliminary FY2025 revenue, cash position, raised 2026–2027 guidance, and SG‑001 plans. |
| Jan 05 | Conference appearance | Neutral | +0.8% | Planned J.P. Morgan Healthcare Conference presentation and webcast details. |
| Nov 05 | Earnings results | Positive | -8.7% | 3Q 2025 revenue, profitability metrics, yield‑enhanced production, and raised guidance. |
Recent fundamental updates have generally been positive, but share reactions have been mixed, with some strong earnings and guidance upgrades met by short-term selloffs.
Over the last several months, ADMA has reported multiple record quarters and years, with FY2025 revenue reaching about $510–511M and strong growth from ASCENIV. Guidance has been raised repeatedly, including FY2026 revenue targets around $630–635M and adjusted EBITDA targets of $355–360M, and longer-term goals above $1.1B revenue and $700M adjusted EBITDA by 2029. The company has emphasized yield‑enhanced production, divestiture of plasma centers for $12M, a growing SG‑001 pipeline, and ongoing share repurchases, providing a backdrop of expanding profitability and active capital allocation for today’s buyback expansion.
Market Pulse Summary
The stock moved +6.5% in the session following this news. A strong positive reaction aligns with ADMA’s announcement of a $125M accelerated share repurchase within a broader $200M 2026 capital return plan. The buyback builds on prior repurchases totaling about $160M since May 2025 and follows record 2025 financials. Investors would need to weigh this capital return against elevated short-term volatility and the stock’s position below its 200-day moving average.
Key Terms
volume-weighted average price technical
rule 10b5-1 trading plans regulatory
sec rule 10b-18 regulatory
AI-generated analysis. Not financial advice.
RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately
“We believe ADMA’s common stock represents the most compelling near-term capital deployment opportunity available to the Company,” said Adam Grossman, President and Chief Executive Officer of ADMA. “Given our sustained revenue growth, expanding margins and an anticipated acceleration in go-forward cash flow generation, we believe we are well positioned to continue investing in our strategic growth initiatives while returning significant capital to stockholders. We view our common stock as meaningfully undervalued relative to the strength and durability of our business and remain highly confident in our ability to drive substantial long-term per-share value.”
Under the terms of the ASR agreement, ADMA will pay JPMorgan an aggregate upfront amount of
The ASR agreement was executed pursuant to the Company’s existing share repurchase program, under which the Company has up to
Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “view,” “positioned,” “support,” “should,” “could,” “would,” “may,” “potential,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s long-term growth trajectory, capital deployment, cash flow forecast, strategic growth initiatives, value of our common stock, ability to deliver stockholder value, timing for completion of the ASR transaction, the number of shares to be purchased by JPMorgan under the ASR agreement, and additional purchases in 2026 under our share repurchase program. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
